AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27001985
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with bortezomib and dexamethasone
Trial: 10872756
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose control group
Trial: 10872756
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose group
Trial: 1899636
Drug: Oral streptokinase-streptodornase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral streptokinase-streptodornase (SS), dosage: two tablets three times a day for eight days
Trial: 12472909
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg day-1
Trial: 580285
Drug: Penfluridol, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penfluridol, administered orally, once weekly
Trial: 23748114
Drug: Fulranumab 6
RxNorm normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab 6 mg every 8 weeks (Q8wk)
Trial: 23748114
Drug: Fulranumab 3
RxNorm normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulranumab 3 mg every 4 weeks (Q4wk)
Trial: 17227809
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone (DG)
Trial: 15287372
Drug: Dynamic exercise
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic exercise during euglycemic insulin clamp
Trial: 15287372
Drug: Dynamic exercise
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic exercise during hyperglycemic insulin clamp
Trial: 11706668
Drug: DEC 300
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 300 mg per day for 12 days
Trial: 9152515
Drug: Selenized yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenized yeast tablet (200 micrograms daily for 4 years)
Trial: 9152515
Drug: Placebo yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo yeast tablet (identical to Se tablet)
Trial: 9152515
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of Se treatment
Trial: 9152515
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of Se treatment
Trial: 8265093
Drug: EAP-1 (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAP-1 (doxorubicin 20 mg/m2 on days 1 and 7, cisplatin 40 mg/m2 on days 2 and 8, etoposide 120 mg/m2 on days 4-6)
Trial: 31385178
Drug: Double-dose nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose nicorandil (30 mg/day)
Trial: 31385178
Drug: Usual-dose nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-dose nicorandil (15 mg/day)
Trial: 25875256
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg twice daily for 12 weeks
Trial: 11496616
Drug: (S)-ketamine/propofol (0.33-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)-ketamine/propofol (0.33-1.0 mg/kg BW/h (S)-ketamine + 1-3 mg/kg BW/h propofol)
Trial: 30541492
Drug: Phase-based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-based Treatment (PBT; maximum of eight sessions skills training followed by eight sessions PE in 16 weeks)
Trial: 26182736
Drug: Capsule Tamsulosin
RxNorm normalized name: tamsulosin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule Tamsulosin 0.4 mg, 1 daily up to 4 weeks
Trial: 26182736
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 Capsule daily up to 4 weeks
Trial: 28984053
Drug: AS04-HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-HPV-16/18 vaccine
Trial: 31315279
Drug: High-CGA coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-CGA coffee (369 mg CGA/serving)
Trial: 31315279
Drug: Control coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control coffee (35 mg CGA/serving)
Trial: 28705592
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (bolus injection of 1.5 mg/kg at induction, continuous infusion of 2 mg/kg/h until end of surgery)
Trial: 24158328
Drug: Microchip implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microchip implantation and control treatments
Trial: 24856612
Drug: Twice-daily NPH
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily NPH
Trial: 9677017
Drug: Elevated plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated plasma total homocysteine concentration (over 11.5 micromol/L)
Trial: 9677017
Drug: Plasma total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma total homocysteine concentration below 11.5 micromol/L
Trial: 18383657
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments (not specified)
Trial: 21797835
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (walking, light, and sleep education)
Trial: 10614791
Drug: Alteplase or
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase or reteplase (thrombolysis treatment)
Trial: 29921041
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of autologous platelet-rich plasma (PRP)
Trial: 25239018
Drug: Daily pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pain assessment using Pain Assessment in Advanced Dementia
Trial: 25239018
Drug: Higher levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher levels of average daily pain
Trial: 17481879
Drug: Budesonide 1600
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 1600 mcg/day for 12 weeks
Trial: 3771951
Drug: Standardized grass
RxNorm normalized name: DACTYLIS GLOMERATA POLLEN 5000 [BAU] in 1 mL / PHLEUM PRATENSE POLLEN 5000 [BAU] in 1 mL INTRADERMAL SOLUTION [Timothy-Orchard Standardized Grass Pollen Mix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized grass extract immunotherapy
Trial: 28025967
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate tablet 50 mg (Jinge®, Test)
Trial: 28025967
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate tablet 100 mg (Viagra®, Reference)
Trial: 9848042
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) (approximately 10 micrograms/kg)
Trial: 8011819
Drug: Meglumine antimonate
RxNorm normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimonate for 10 days plus alternate-day injections of interferon-gamma
Trial: 29629828
Drug: Telephone-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive-behavioral therapy (T-CBT)
Trial: 26086603
Drug: High loading
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High loading dose of Rosuvastatin before PCI (n = 264)
Trial: 26086603
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n = 264)
Trial: 16427545
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (100 mg/kg before skin incision followed by 1 g/hour continuous infusion until chest closure, 10 g in cardiopulmonary bypass circuit)
Trial: 10971859
Drug: EPD (immunotherapy)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPD (immunotherapy)
Trial: 8226141
Drug: Fast neutron
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast neutron radiation therapy
Trial: 6439700
Drug: Conventional photon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photon radiation therapy
Trial: 28833748
Drug: Cognitive rehabilitation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation, cognitive behavioural therapy, and life review methods
Trial: 21134123
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 650mg q4h
Trial: 16780480
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% potassium hydroxide solution
Trial: 14533336
Drug: Orthodontic Oral-B
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic Oral-B
Trial: 14533336
Drug: Oral-B Advantage
RxNorm normalized name: Advantage Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Advantage 30
Trial: 8649700
Drug: Weekly stripping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly stripping of membranes
Trial: 8649700
Drug: Weekly gentle
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly gentle cervical examinations
Trial: 1371197
Drug: Donor-specific transfusions
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor-specific transfusions (DST) and continuous intravenous cyclosporine (CsA) initiated 24 hr before transplantation
Trial: 30773542
Drug: 4 °C
RxNorm normalized name: The full generic name for the drug abbreviation '4 °C' is not clear from the information provided. The abbreviation '4 °C' typically refers to a temperature of 4 degrees Celsius, which is a common storage or incubation temperature used in various laboratory and clinical procedures, but it does not represent a specific drug or medication.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 °C RF‐APGD plasma jet treatment for 20 s
Trial: 25730292
Drug: Topical liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical liposomal lidocaine
Trial: 11560538
Drug: 15 mg/d
RxNorm normalized name: Valtoco, 15 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/d of sibutramine intermittently during weeks 1-12, 19-30, and 37-48 (n = 395)
Trial: 19848198
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatment only)
Trial: 3382461
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg cianopramine (acute administration)
Trial: 3382461
Drug: 1, 2,
RxNorm normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, and 3 mg cianopramine (chronic administration)
Trial: 3382461
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg cianopramine (superimposed single dose after chronic administration)
Trial: 10551706
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs)
Trial: 23548855
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (440 mg of Mg oxide 3 times per week for 6 months)
Trial: 21518840
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg efavirenz with 600 mg rifampin/day
Trial: 8568310
Drug: US inactivated
RxNorm normalized name: Rabies virus inactivated antigen, A
DrugBank: Rabies virus inactivated antigen, A (DB10283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US inactivated split-virus vaccine
Trial: 25748698
Drug: hANP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hANP + DA (1-3 μg·kg·min)
Trial: 25748698
Drug: hANP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hANP + furosemide (10-30 mg injection)
Trial: 22737876
Drug: Compound betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound betamethasone injection 1 ml and benzathine penicillin 1 200 000 U, deeply injected into muscles on hips, one time.
Trial: 22737876
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg orally once a day and amoxicillin capsules 0.5 mg orally three times a day, taken for one week.
Trial: 17610528
Drug: TMC114/r (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC114/r (300/100 mg bid) plus TDF (300 mg qd)
Trial: 17610528
Drug: TMC114/r (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC114/r (300/100 mg bid)
Trial: 11937314
Drug: PVACE‐BOP therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVACE‐BOP therapy in the poorest risk group
Trial: 10200005
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone at 1 mg/kg/dose (maximum 60 mg/dose) four times daily
Trial: 1825568
Drug: GR32191 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR32191 (80 mg po and 40 mg po)
Trial: 29199012
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of CLS‐TA
Trial: 25244776
Drug: Yupingfeng droppill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yupingfeng droppill and cetirizine tablets
Trial: 25244776
Drug: Cetirizine tablets
RxNorm normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine tablets
Trial: 21877203
Drug: Tenofovir 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir 1% gel (CT cohort)
Trial: 12209372
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (yoghurt enriched with L. acidophilus 145, B. longum 913 and 1% oligofructose)
Trial: 10023014
Drug: subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous epoetin á 150 U/kg three times a week for up to 12 consecutive weeks (Group A)
Trial: 10023014
Drug: subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous epoetin á 50 U/kg daily for up to 12 consecutive weeks (Group B)
Trial: 2676173
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release isosorbide-5-mononitrate (ISM) 60 mg
Trial: 2857210
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg twice a day
Trial: 25720388
Drug: Intravenous exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous exenatide
Trial: 11304934
Drug: Doxepin-ratiopharm 25
RxNorm normalized name: doxepin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin-ratiopharm 25 mg film-coated tablets (test preparation)
Trial: 6539187
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine
Trial: 3552464
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg albuterol (Salbutamol)
Trial: 29346473
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in primary care
Trial: 24116853
Drug: Adjunctive brivaracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive brivaracetam (BRV) 20-150 mg/day
Trial: 18587525
Drug: Cu-(II)-orotate-dihydrate; 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cu-(II)-orotate-dihydrate; 8 mg Cu daily
Trial: 11874243
Drug: Nasal SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal SCT (200 IU daily)
Trial: 2346342
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of atropine
Trial: 19252346
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/day) + Sibutramine (10 mg/day)
Trial: 19252346
Drug: Metformin (3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (3,000 mg/day) + Sibutramine (10 mg/day)
Trial: 16298763
Drug: Enzogenol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol (480 mg) and vitamin C (60 mg)
Trial: 16298763
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (60 mg) alone
Trial: 8431330
Drug: Midazolam 3-10
RxNorm normalized name: midazolam 14.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3-10 mg
Trial: 3583405
Drug: Desipramine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (specific inhibitor of neuronal uptake)
Trial: 3583405
Drug: Hydrocortisone (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (highest dose without neuronal uptake inhibition)
Trial: 28709817
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line treatment with daily oral antihistamine
Trial: 28709817
Drug: Second line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second line treatment with higher dose antihistamine
Trial: 28709817
Drug: Third line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third line treatment with omalizumab or cyclosporine
Trial: 28777519
Drug: Surgical intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical intervention without HBO₂ therapy (Group 1)
Trial: 7532763
Drug: Anipamil 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anipamil 80 mg once daily
Trial: 7532763
Drug: Anipamil 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anipamil 160 mg once daily
Trial: 2442550
Drug: Lisinopril (LIS)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (LIS) 20, 40, and 80 mg
Trial: 2442550
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5, 25, and 50 mg
Trial: 2442550
Drug: Lisinopril +
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril + Hydrochlorothiazide (LIS + HCTZ) 20 + 12.5, 40 + 25, and 80 + 50 mg
Trial: 31822399
Drug: Selinexor (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (35 or 50 mg/m2 twice‐weekly [BIW] or 50 mg/m2 once‐weekly [QW])
Trial: 31822399
Drug: Selinexor (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (50 mg/m2 QW)
Trial: 30768411
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for anxiety
Trial: 29603219
Drug: Child-centered therapy
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-centered therapy (CCT)
Trial: 28238674
Drug: Participatory Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participatory Action Research (PAR) weekly sessions
Trial: 28238674
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (weekly reminiscence activity)
Trial: 23615633
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with telmisartan (80 mg/d) and aliskiren (300 mg/d)
Trial: 23615633
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with telmisartan (160 mg/d) alone
Trial: 23615633
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with telmisartan (80 mg/d) and eplerenone (50 mg/d)
Trial: 21840177
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (twice daily for 14 days)